Use this link to cite:
https://hdl.handle.net/2183/45740 Immunosuppressive therapy and infection after kidney transplantation
Loading...
Identifiers
Publication date
Authors
Fortún, Jesús
Martín-Dávila, Pilar
Pascual, Julio F.
Cervera, Carlos
Moreno, Asunción V.
Gavalda, J.
Aguado, José María
Pereira, Porfirio
Gurgui, Mercé
Carratalá, Jordi A.
Advisors
Other responsabilities
Journal Title
Bibliographic citation
Fortun J, Martin-Davila P, Pascual J, Cervera C, Moreno A, Gavalda J, Aguado JM, Pereira P, Gurguí M, Carratala J, Fogueda M, Montejo M, Blasco F, Bou G, Torre-Cisneros J; RESITRA Transplant Network. Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis. 2010 Oct;12(5):397-405.
Type of academic work
Academic degree
Abstract
[Abstract]
Background: The role of immunosuppressive drugs in the development of infection in transplant recipients has been poorly analyzed.
Objective: To evaluate the possible association between infection and immunosuppression regimens in a large cohort of renal transplant recipients.
Methods: All renal transplant recipients included in the RESITRA prospective cohort from August 2003 to February 2005 with a minimum follow-up of 3 months were studied. An intention-to-treat analysis was performed and patients were analyzed in groups according to the type of induction and initial maintenance therapy. Viral, bacterial, and fungal infections occurring during this period were evaluated.
Results: A total of 1398 renal transplant recipients were studied. A maintenance regimen containing sirolimus was independently associated with a lower risk of cytomegalovirus (CMV) infection (odds ratio [OR], 0.16; 95% confidence interval [CI], 0.05-0.54) and with a higher rate of surgical site infection (OR, 3.21; 95% CI, 1.26-8.21). Excluding treatment used for acute rejection episodes, no other factors related to the immunosuppression regimens were associated with the development of bacteremia, urinary infections, pneumonia, or other infections.
Conclusion: The use of sirolimus as maintenance therapy in kidney recipients is associated with a low rate of CMV infection and with a higher risk of surgical site infection.
Description
Editor version
Rights
This is the peer reviewed version of the article, which has been published in final form at Wiley Online Library. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties.